Cargando…

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated (212)Pb-based alpha therapy using its (203)Pb imaging analogue. METHODS: Four novel Glu...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, José Carlos, Schäfer, Martin, Bauder-Wüst, Ulrike, Lehnert, Wencke, Leotta, Karin, Morgenstern, Alfred, Kopka, Klaus, Haberkorn, Uwe, Mier, Walter, Kratochwil, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451745/
https://www.ncbi.nlm.nih.gov/pubmed/30603987
http://dx.doi.org/10.1007/s00259-018-4220-z
_version_ 1783409206923100160
author dos Santos, José Carlos
Schäfer, Martin
Bauder-Wüst, Ulrike
Lehnert, Wencke
Leotta, Karin
Morgenstern, Alfred
Kopka, Klaus
Haberkorn, Uwe
Mier, Walter
Kratochwil, Clemens
author_facet dos Santos, José Carlos
Schäfer, Martin
Bauder-Wüst, Ulrike
Lehnert, Wencke
Leotta, Karin
Morgenstern, Alfred
Kopka, Klaus
Haberkorn, Uwe
Mier, Walter
Kratochwil, Clemens
author_sort dos Santos, José Carlos
collection PubMed
description PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated (212)Pb-based alpha therapy using its (203)Pb imaging analogue. METHODS: Four novel Glu-urea-based ligands containing the chelators p-SCN-Bn-TCMC or DO3AM were synthesized. Affinity and PSMA-specific internalization were studied in C4-2 cells, and biodistribution in C4-2 tumour-bearing mice. The most promising compound, (203)Pb-CA012, was transferred to clinical use. Two patients underwent planar scintigraphy scans at 0.4, 4, 18, 28 and 42 h after injection, together with urine and blood sampling. The time–activity curves of source organs were extrapolated from (203)Pb to (212)Pb and the calculated residence times of (212)Pb were forwarded to its unstable daughter nuclides. QDOSE and OLINDA were used for dosimetry calculations. RESULTS: In vitro, all ligands showed low nanomolar binding affinities for PSMA. CA09 and CA012 additionally showed specific ligand-induced internalization of 27.4 ± 2.4 and 15.6 ± 2.1 %ID/10(6) cells, respectively. The (203)Pb-labelled PSMA ligands were stable in serum for 72 h. In vivo, CA012 showed higher specific uptake in tumours than in other organs, and particularly showed rapid kidney clearance from 5.1 ± 2.5%ID/g at 1 h after injection to 0.9 ± 0.1%ID/g at 24 h. In patients, the estimated effective dose from 250–300 MBq of diagnostic (203)Pb-CA012 was 6–7 mSv. Assuming instant decay of daughter nuclides, the equivalent doses projected from a therapeutic activity of 100 MBq of (212)Pb-CA012 were 0.6 Sv(RBE5) to the red marrow, 4.3 Sv(RBE5) to the salivary glands, 4.9 Sv(RBE5) to the kidneys, 0.7 Sv(RBE5) to the liver and 0.2 Sv(RBE5) to other organs; representative tumour lesions averaged 13.2 Sv(RBE5) (where RBE5 is relative biological effectiveness factor 5). Compared to clinical experience with (213)Bi-PSMA-617 and (225)Ac-PSMA-617, the projected maximum tolerable dose was about 150 MBq per cycle. CONCLUSION: (212)Pb-CA012 is a promising candidate for PSMA-targeted alpha therapy of prostate cancer. The dosimetry estimate for radiopharmaceuticals decaying with the release of unstable daughter nuclides has some inherent limitations, thus clinical translation should be done cautiously. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4220-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6451745
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64517452019-04-23 Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? dos Santos, José Carlos Schäfer, Martin Bauder-Wüst, Ulrike Lehnert, Wencke Leotta, Karin Morgenstern, Alfred Kopka, Klaus Haberkorn, Uwe Mier, Walter Kratochwil, Clemens Eur J Nucl Med Mol Imaging Original Article PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated (212)Pb-based alpha therapy using its (203)Pb imaging analogue. METHODS: Four novel Glu-urea-based ligands containing the chelators p-SCN-Bn-TCMC or DO3AM were synthesized. Affinity and PSMA-specific internalization were studied in C4-2 cells, and biodistribution in C4-2 tumour-bearing mice. The most promising compound, (203)Pb-CA012, was transferred to clinical use. Two patients underwent planar scintigraphy scans at 0.4, 4, 18, 28 and 42 h after injection, together with urine and blood sampling. The time–activity curves of source organs were extrapolated from (203)Pb to (212)Pb and the calculated residence times of (212)Pb were forwarded to its unstable daughter nuclides. QDOSE and OLINDA were used for dosimetry calculations. RESULTS: In vitro, all ligands showed low nanomolar binding affinities for PSMA. CA09 and CA012 additionally showed specific ligand-induced internalization of 27.4 ± 2.4 and 15.6 ± 2.1 %ID/10(6) cells, respectively. The (203)Pb-labelled PSMA ligands were stable in serum for 72 h. In vivo, CA012 showed higher specific uptake in tumours than in other organs, and particularly showed rapid kidney clearance from 5.1 ± 2.5%ID/g at 1 h after injection to 0.9 ± 0.1%ID/g at 24 h. In patients, the estimated effective dose from 250–300 MBq of diagnostic (203)Pb-CA012 was 6–7 mSv. Assuming instant decay of daughter nuclides, the equivalent doses projected from a therapeutic activity of 100 MBq of (212)Pb-CA012 were 0.6 Sv(RBE5) to the red marrow, 4.3 Sv(RBE5) to the salivary glands, 4.9 Sv(RBE5) to the kidneys, 0.7 Sv(RBE5) to the liver and 0.2 Sv(RBE5) to other organs; representative tumour lesions averaged 13.2 Sv(RBE5) (where RBE5 is relative biological effectiveness factor 5). Compared to clinical experience with (213)Bi-PSMA-617 and (225)Ac-PSMA-617, the projected maximum tolerable dose was about 150 MBq per cycle. CONCLUSION: (212)Pb-CA012 is a promising candidate for PSMA-targeted alpha therapy of prostate cancer. The dosimetry estimate for radiopharmaceuticals decaying with the release of unstable daughter nuclides has some inherent limitations, thus clinical translation should be done cautiously. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4220-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-01-03 2019 /pmc/articles/PMC6451745/ /pubmed/30603987 http://dx.doi.org/10.1007/s00259-018-4220-z Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
dos Santos, José Carlos
Schäfer, Martin
Bauder-Wüst, Ulrike
Lehnert, Wencke
Leotta, Karin
Morgenstern, Alfred
Kopka, Klaus
Haberkorn, Uwe
Mier, Walter
Kratochwil, Clemens
Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title_full Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title_fullStr Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title_full_unstemmed Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title_short Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
title_sort development and dosimetry of (203)pb/(212)pb-labelled psma ligands: bringing “the lead” into psma-targeted alpha therapy?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451745/
https://www.ncbi.nlm.nih.gov/pubmed/30603987
http://dx.doi.org/10.1007/s00259-018-4220-z
work_keys_str_mv AT dossantosjosecarlos developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT schafermartin developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT bauderwustulrike developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT lehnertwencke developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT leottakarin developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT morgensternalfred developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT kopkaklaus developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT haberkornuwe developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT mierwalter developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy
AT kratochwilclemens developmentanddosimetryof203pb212pblabelledpsmaligandsbringingtheleadintopsmatargetedalphatherapy